Milestone Pharmaceuticals Inc. (MIST) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $150.64M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Joseph G. Oliveto |
| IPO Date | 2019-05-09 | CAGR | — |
| Employees | 38 | Website | www.milestonepharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $93.62M | P/E | -1.78 | Forward P/E | -1.57 | PEG | — |
| P/S | 116.18 | P/B | 16.63 | P/CF | -7.86 | P/FCF | -7.06 |
| Sales | $2.34M | Sales 1Y | inf% | Sales 3Y | -60.95% | Sales 5Y | -84.38% |
| EPS | $-0.68 | EPS 1Y | -18.82% | EPS 3Y | -49.26% | EPS 5Y | -28.87% |
| Sales QoQ | 134.87% | EPS QoQ | 5% | Sales QoQ Avg | — | EPS QoQ Avg | 5.83% |
| Gross Margin | 94.58% | Operating Margin | -3353.01% | Profit Margin | -3585.62% | ROCE | -49.27% |
| ROA | -46% | ROE | -288% | Altman Z Score | -3.46 | Piotroski Score | 4 |
| Current Ratio | 8.13 | Quick Ratio | 7.92 | Cash Ratio | 7.65 | Op. CF Ratio | — |
| Debt/Equity | 3.3 | Debt/Assets | 0.33 | Lt Debt/Equity | 3.26 | Lt Debt/Cap. | 0.76 |
| Intrst Cov. | -7.27 | Inventory Turnover | 0.03 | Asset Turnover | 0.01 | Receivables Turnover | 0.59 |
| Enterprise Value | $93.62M | P/E Ratio | -1.78 |
| Forward P/E | -1.57 | PEG Ratio | — |
| P/S Ratio | 116.18 | P/B Ratio | 16.63 |
| P/CF Ratio | -7.86 | P/FCF Ratio | -7.06 |
| EPS | $-0.68 | EPS Growth 1Y | -18.82% |
| EPS Growth 3Y | -49.26% | EPS Growth 5Y | -28.87% |
| Revenue Growth 1Y | inf% | Gross Margin | 0.95% |
| Operating Margin | -33.53% | Profit Margin | -35.86% |
| ROE | -2.88% | ROA | -0.46% |
| ROCE | -0.49% | Current Ratio | 8.13 |
| Quick Ratio | 7.92 | Cash Ratio | 7.65 |
| Debt/Equity | 3.3 | Interest Coverage | -7.27 |
| Altman Z Score | -3.46 | Piotroski Score | 4 |
Milestone Pharmaceuticals Inc. (MIST) valuation & financials
Milestone Pharmaceuticals Inc. (MIST) has a market capitalization of $150.64M and trades at a price-to-earnings ratio of -1.8. It operates in the Healthcare sector (Biotechnology).
Milestone Pharmaceuticals Inc.'s revenue grew +inf% over the last year.
Milestone Pharmaceuticals Inc.'s next earnings report is scheduled for November 11, 2026 before market open; analysts estimate EPS of $-0.20. Check the earnings calendar to see all companies reporting this week.
Milestone Pharmaceuticals Inc. (MIST) — frequently asked questions
When does Milestone Pharmaceuticals Inc. (MIST) report earnings next?
Milestone Pharmaceuticals Inc. is expected to report earnings on November 11, 2026 before market open. Analysts estimate EPS of $-0.20.
What is Milestone Pharmaceuticals Inc.'s market cap?
Milestone Pharmaceuticals Inc. (MIST) has a market capitalization of $150.64M.
What is MIST's P/E ratio?
Milestone Pharmaceuticals Inc. trades at a price-to-earnings ratio of -1.8, with trailing twelve-month EPS of $-0.68.
How fast is Milestone Pharmaceuticals Inc. growing?
Milestone Pharmaceuticals Inc.'s revenue grew +inf% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)